Gilead Sciences, Inc. (GILD)
NASDAQ: GILD · Real-Time Price · USD
170.68
+5.07 (3.06%)
At close: Oct 30, 2026, 4:00 PM EDT
170.00
-0.68 (-0.40%)
After-hours: Oct 30, 2026, 7:59 PM EDT
Gilead Sciences Revenue
Gilead Sciences had revenue of $8.30B in the quarter ending September 30, 2026, with 6.83% growth. This brings the company's total for the last twelve months to $30.99B, up 6.54% year-over-year. In the year 2025, Gilead Sciences had annual revenue of $29.44B with 2.40% growth. That makes Gilead Sciences the 448th largest company in the world by revenue and 158th in the United States.
Revenue (ttm)
$30.99B
Revenue Growth
+6.54%
P/S Ratio
6.83
Revenue / Employee
$1,822,824
Employees
17,000
Market Cap
211.70B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Gilead Sciences breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 29.44B | 689.00M | 2.40% |
| Dec 31, 2024 | 28.75B | 1.64B | 6.04% |
| Dec 31, 2023 | 27.12B | -165.00M | -0.60% |
| Dec 31, 2022 | 27.28B | -24.00M | -0.09% |
| Dec 31, 2021 | 27.31B | 2.62B | 10.60% |
| Dec 31, 2020 | 24.69B | 2.24B | 9.98% |
| Dec 31, 2019 | 22.45B | 322.00M | 1.46% |
| Dec 31, 2018 | 22.13B | -3.98B | -15.24% |
| Dec 31, 2017 | 26.11B | -4.28B | -14.09% |
| Dec 31, 2016 | 30.39B | -2.25B | -6.89% |
| Dec 31, 2015 | 32.64B | 7.75B | 31.13% |
| Dec 31, 2014 | 24.89B | 13.69B | 122.19% |
| Dec 31, 2013 | 11.20B | 1.50B | 15.46% |
| Dec 31, 2012 | 9.70B | 1.32B | 15.70% |
| Dec 31, 2011 | 8.39B | 435.97M | 5.48% |
| Dec 31, 2010 | 7.95B | 938.04M | 13.38% |
| Dec 31, 2009 | 7.01B | 1.68B | 31.40% |
| Dec 31, 2008 | 5.34B | 1.11B | 26.14% |
| Dec 31, 2007 | 4.23B | 1.20B | 39.78% |
| Dec 31, 2006 | 3.03B | 997.74M | 49.19% |
| Dec 31, 2005 | 2.03B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 99.34B |
| Merck & Co. | 67.38B |
| AbbVie | 64.39B |
| Pfizer | 63.70B |
| AstraZeneca | 61.37B |
| Novartis AG | 57.36B |
| Sanofi | 55.89B |
| Novo Nordisk | 50.34B |
GILD News
- 1 day ago - Gilead Sciences to Present at Upcoming Fourth Quarter 2026 Investor Conferences - Business Wire
- 1 day ago - Gilead price target raised to $200 from $177 at Scotiabank - TheFly
- 1 day ago - Gilead price target raised to $183 from $163 at Morgan Stanley - TheFly
- 1 day ago - Gilead price target raised to $190 from $170 at JPMorgan - TheFly
- 1 day ago - Gilead price target raised to $181 from $158 at Truist - TheFly
- 1 day ago - Gilead price target raised to $175 from $160 at TD Cowen - TheFly
- 1 day ago - Gilead price target raised to $195 from $175 at UBS - TheFly
- 1 day ago - Gilead price target raised to $175 from $155 at Cantor Fitzgerald - TheFly